Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management
Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share (AMRN)
Last amarin corporation plc - american depositary shares, each representing one ordinary share earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.amarincorp.com/investors
Company Research
Source: GlobeNewswire
Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa®Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today provided an update on the growing interest in information on Amarin’s REDUCE-IT™ study and the potential for use of Vascepa® (icosapent ethyl) in studied patients at risk for a cardiovascular event. Cardiovascular disease (CVD) is worldwide the #1 killer of men and women.1,2 REDUCE-IT studied the effects of Vascepa on the reduction of major adverse cardiovascular events in a high-risk patient population. The study results are currently under regulatory review in the United States and Canada. Publications Increasingly Highlight REDUCE-IT and Vascepa Publications and other scientific discussions h
Show less
Read more
Impact Snapshot
Event Time:
AMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024GlobeNewswire
- Metastatic Liver Cancer Pipeline Insight 2024, Featuring Key Players Oncorus, Sirnaomics, Codiak BioSciences, RemeGen, Amarin, Medivir, AstraZeneca, Amal Therapeutics and Boehringer Ingelheim [Yahoo! Finance]Yahoo! Finance
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24GlobeNewswire
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups [Yahoo! Finance]Yahoo! Finance
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsGlobeNewswire
AMRN
Earnings
- 2/29/24 - Beat
AMRN
Sec Filings
- 4/19/24 - Form 4
- 4/19/24 - Form 4
- 4/19/24 - Form 4
- AMRN's page on the SEC website